Multiplex bead-array competitive immunoassay for simultaneous detection of three pesticides in vegetables

2013 ◽  
Vol 180 (5-6) ◽  
pp. 387-395 ◽  
Author(s):  
Yirong Guo ◽  
Jie Tian ◽  
Chizhou Liang ◽  
Guonian Zhu ◽  
Wenjun Gui
Keyword(s):  
Simultaneous Detection ◽  
Competitive Immunoassay ◽  
Multiplex Bead

scholarly journals Development of a Multiplex Bead Assay for Simultaneous Serodiagnosis of Antibodies against Mycobacterium bovis, Brucella suis, and Trichinella spiralis in Wild Boar

2021 ◽  
Vol 9 (5) ◽  
pp. 904
Author(s):  
Antonia Touloudi ◽  
George Valiakos ◽  
Shaun Cawthraw ◽  
Polychronis Kostoulas ◽  
Christian Gortázar ◽  
...  
Keyword(s):  
Wild Boar ◽  
Mycobacterium Bovis ◽  
Magnetic Beads ◽  
Trichinella Spiralis ◽  
Simultaneous Detection ◽  
Multiplex Assay ◽  
Diagnostic Potential ◽  
Serological Status ◽  
Brucella Suis ◽  
Multiplex Bead

The aim of this study was to evaluate the diagnostic performance of a multiplex bead assay for the simultaneous detection of antibodies against Mycobacterium bovis, Brucella suis, and Trichinella spiralis. Sera from Eurasian wild boar of known serological status for TB (64 seropositive, 106 seronegative), Brucella (30 seropositive, 39 seronegative), and Trichinella (21 seropositive, 97 seronegative) were used for the development and evaluation of the assay. Magnetic beads coated with recombinant MPB83 antigen (TB), a whole-cell B. suis 1330 antigen, and an E/S T. spiralis antigen were used for the detection of specific antibodies using Bio-Rad Bio-Plex technology. The sensitivities (Se) and specificities (Sp) of the multiplex assay were, for M. bovis, 0.98 and 0.86; for B. suis, 1.00 and 0.97; and for T. spiralis, 0.90 and 0.99 (Se and Sp, respectively). The results show the diagnostic potential of this assay for the simultaneous detection of antibodies against M. bovis, B. suis, and T. spiralis in wild boar.

Simultaneous Detection of Major Fusion Transcripts in CML, ALL and AML Leukemias in a Multiplex Bead-Array Assay.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4525-4525
Author(s):  
Fei Ye ◽  
Brad Mire ◽  
Ila Wolf ◽  
Cora Lahey ◽  
Andrew G. Hadd
Keyword(s):  
Simultaneous Detection ◽  
Splice Junction ◽  
Fusion Transcript ◽  
Fusion Transcripts ◽  
Chromosome Translocations ◽  
Short Forms ◽  
Clinical Detection ◽  
Prognostic Implications ◽  
Multiplex Bead

Abstract INTRODUCTION: Accurate sub-classification of leukemia-associated chromosome translocations is essential for precise risk-stratified diagnosis and improvement of treatment outcomes. We have developed a rapid assay system to detect the nine most common chromosomal translocations covering three different leukemia disease groups: CML, ALL and AML. The purpose of our study was to confirm clinical detection of twelve translocation markers. MATERIALS AND METHODS: The liquid bead array assay combined multiplex RT-PCR with signal readout in a 96-well plate format. RNA fusion transcripts of leukemia-associated chromosome translocations were reverse transcribed into cDNA and amplified by multiplex PCR using biotin-modified primers. An endogeneous control gene, GAPDH, was co-amplified in each sample and concurrently analyzed. A single-tube bead array contained 11 marker specific oligonucleotide probes with sequences complimentary to the fusion transcript splice junction for the following markers: b2a2, b3a2 for CML; e1a2, E2A-PBX1, TEL/AML1 and MLL/AF4 (e10/e4, e9/e5) for ALL; PML/RARa (long and short forms), AML1-ETO and inv(16) (A and D types) for AML. Biotinylated amplified products were hybridized to the array without intervening purification steps. After incubation with streptavidin-conjugated fluorophore, the reaction mixtures were analyzed by the Luminex platform. RESULTS: RNA samples from translocation-positive cell lines and IVT products were detected with less than 10% CVs in approximately five hours. Long and short forms of PML-RARa and A and D types of inv(16) were specifically resolved. The assay can detect two MLL/AF4 subtypes: MLL/AF4 (e10/e4) or MLL/AF4 (e9/e5). Eighty-seven leukemia patient samples (RNAs extracted from peripheral blood and bone marrow) were screened and all translocations were correctly detected. A software system for selective readout based on disease class was implemented. CONCLUSIONS: This multiplex array-based assay can be an effective and reliable tool in the clinical screening of leukemia patients for the presence of specific fusion transcripts with important diagnostic and prognostic implications.

Simultaneous Detection of Seven Drugs of Abuse by the TriageTM Panel for Drugs of Abuse

1992 ◽  
Vol 38 (9) ◽  
pp. 1678-1684 ◽  
Author(s):  
K F Buechler ◽  
S Moi ◽  
B Noar ◽  
D McGrath ◽  
J Villela ◽  
...  
Keyword(s):  
Urine Sample ◽  
Drug Class ◽  
Drugs Of Abuse ◽  
Solid Phase ◽  
Simultaneous Detection ◽  
Threshold Concentration ◽  
Competitive Immunoassay ◽  
Immobilized Antibodies ◽  
Procedural Control ◽  
To Come

Abstract This novel, competitive immunoassay simultaneously detects seven drugs of abuse in urine. A urine sample is placed in contact with lyophilized reagents, the reaction mixture is allowed to come to equilibrium (10 min), and then the whole mixture is applied to a solid phase that contains various immobilized antibodies in discrete drug-class-specific zones. After a washing step, the operator visually examines each zone for the presence of a red bar. The method incorporates present threshold concentrations that are independent for each drug. In the absence of drug or in the presence of drug in quantities less than the threshold concentration, no colored bar is visible. Samples containing drug(s) at or above the threshold concentration cause a red bar to appear for the appropriate drug(s). Positive and negative procedural control zones are incorporated into each determination. The performance of the assay methodology matches that of instrumented immunoassay systems.

Wound age estimation by simultaneous detection of 9 cytokines in human dermal wounds with a multiplex bead-based immunoassay: An estimative method using outsourced examinations

2009 ◽  
Vol 11 (4) ◽  
pp. 186-190 ◽  
Author(s):  
Masataka Takamiya ◽  
Hitoshi Biwasaka ◽  
Kiyoshi Saigusa ◽  
Nori Nakayashiki ◽  
Yasuhiro Aoki
Keyword(s):  
Age Estimation ◽  
Simultaneous Detection ◽  
Wound Age ◽  
Multiplex Bead

scholarly journals Evaluation of a Multiplex Flow Immunoassay for Detection of Epstein-Barr Virus-Specific Antibodies

2008 ◽  
Vol 15 (9) ◽  
pp. 1410-1413 ◽  
Author(s):  
M. J. Binnicker ◽  
D. J. Jespersen ◽  
J. A. Harring ◽  
L. O. Rollins ◽  
E. M. Beito
Keyword(s):  
Specific Antibody ◽  
Epstein Barr Virus ◽  
Simultaneous Detection ◽  
Nuclear Antigen ◽  
Antibody Testing ◽  
Past Infection ◽  
Specific Antibodies ◽  
Barr Virus ◽  
Epstein Barr ◽  
Multiplex Bead

ABSTRACT Conventional methods for the detection of Epstein-Barr virus (EBV)-specific antibodies include the immunofluorescence assay (IFA) and enzyme immunoassay (EIA). While sensitive and specific, these methods are labor-intensive and require separate assays for each analyte. This study evaluated the performance of a multiplex bead assay (BioPlex 2200; Bio-Rad Laboratories, Hercules, CA) for the simultaneous detection of immunoglobulin G (IgG) and IgM class antibodies to the EBV viral capsid antigen (VCA) and IgG class antibodies to Epstein-Barr virus nuclear antigen-1 (EBNA-1). Serum specimens (n = 1,315) submitted for routine EBV-specific antibody testing by EIA (Grifols-Quest, Inc., Miami, FL) were also tested by the multiplex bead assay using the BioPlex 2200 automated analyzer. Specimens showing discordant results were tested by IFA. Following IFA resolution, the BioPlex VCA IgM, VCA IgG, and EBNA-1 IgG assays demonstrated 97.9%, 91.4%, and 96.9% agreement, respectively, with the results obtained by EIA. Furthermore, the BioPlex assays showed an overall agreement of 94.1% with the EIA when the specimens were categorized by disease state (susceptible, acute, or past infection) based on the EBV-specific antibody profiles. These findings indicate that the BioPlex EBV assays demonstrate a performance comparable to that of the conventional EIA, while allowing for a more rapid (2.3 h for 100 samples versus 4.5 h by the EIA) and higher-throughput (∼400 samples per 9 h versus 200 samples by the EIA) analysis of the EBV-specific antibody response.

scholarly journals Evaluation of the Bio-Rad BioPlex Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG Multiplex Bead Immunoassay

2011 ◽  
Vol 18 (9) ◽  
pp. 1524-1526 ◽  
Author(s):  
Matthew J. Binnicker ◽  
Deborah J. Jespersen ◽  
Leonard O. Rollins
Keyword(s):  
Varicella Zoster Virus ◽  
Simultaneous Detection ◽  
Turnaround Time ◽  
Complete Analysis ◽  
Reference Laboratory ◽  
Routine Testing ◽  
Varicella Zoster ◽  
Comparable Performance ◽  
Multiplex Bead ◽  
Virus Assays

ABSTRACTThe goal of this study was to compare the BioPlex 2200 measles, mumps, rubella, and varicella-zoster virus (MMRV) IgG multiplex assays (Bio-Rad Laboratories, Hercules, CA) to routine testing by enzyme immunoassay (EIA). Serum specimens (n= 500) submitted to our reference laboratory for routine MMRV IgG testing by EIA were also tested by the BioPlex assays. Following testing, the BioPlex measles, mumps, rubella, and varicella-zoster virus assays demonstrated agreements of 91.6% (95% confidence interval [CI], 88.8% to 93.7%), 94.2% (95% CI, 91.7% to 95.7%), 94.4% (95% CI, 92.0% to 96.1%), and 91.8% (95% CI, 89.0% to 93.9%), respectively, compared to the results of EIA. Timing studies showed that the BioPlex MMRV assay could provide complete analysis of 100 serum specimens in 1.7 h, compared to 5.5 h by EIA. These data indicate that the BioPlex MMRV IgG assays exhibit comparable performance (93% overall agreement [1,860/2,000 results]; κ = 0.67) to routine testing by EIA. The BioPlex assays allow for the simultaneous detection of all four analytes, thereby eliminating potential aliquot errors and reducing turnaround time.

Sign in / Sign up

Export Citation Format

Share Document